Legal Representation
Attorney
Melissa W. Woo-Allen
USPTO Deadlines
Application History
15 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 9, 2020 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Mar 9, 2020 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 6, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 11, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 11, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 22, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 6, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 22, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 19, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 19, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Apr 19, 2019 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 19, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 19, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 1, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 11, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of glaucoma and hypertension
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the word "ROCKLATAN" in lower case block letters with "ROCK" in a darker shade than "LATAN" and in between four curved bands, which create the impression of parentheses, one dark and one light curved band before "ROCKLATAN" and one light and one dark curved band after "ROCKLATAN" with the words "(NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%" beneath the word "ROCKLATAN".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"(NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%"